Innate Pharma (IPHA) AI Stock Analysis

Company Guidance

Innate is targeting the first patient in TELLOMAK-3 in Q1 2027, with the first patient expected in the first quarter of 2027 and a filing for accelerated approval in Sezary Syndrome currently planned for the second half of 2027; initial Phase 1 dose escalation data for IPH4.5 thousand are expected on November 18, 2026, with approximately 15 patients enrolled in both post TB urothelial cancer, head and neck cancer, and somewhat lower enrollment in the non-small cell lung cancer cohort; the PACIFIC-9 Phase 3 readout remains expected in the second half of 2026, with a press release from AstraZeneca and Innate also looking to press release that as well and potentially do some calls; the $75 million Sobi upfront payment and €30 million equity offering, representing €28 million in expected net proceeds, are expected to extend cash runway through the end of the first quarter of 2028; lacutamab pricing research established a range of $500 thousand to $650 thousand per patient per annum; and the €30 million raise funds the initial steps into dose optimization, while broadening the program across additional tumor types would require additional funding.